PTC Therapeutics (PTCT) – Investment Analysts’ Recent Ratings Updates

PTC Therapeutics (NASDAQ: PTCT) has recently received a number of price target changes and ratings updates:

• 2/18/2025 – PTC Therapeutics had its price target raised by analysts at Royal Bank of Canada from $60.00 to $63.00. They now have an “outperform” rating on the stock.
• 2/17/2025 – PTC Therapeutics was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 2/12/2025 – PTC Therapeutics had its price target raised by analysts at Citigroup Inc. from $32.00 to $45.00. They now have a “sell” rating on the stock.
• 2/7/2025 – PTC Therapeutics was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 2/3/2025 – PTC Therapeutics had its price target raised by analysts at Cantor Fitzgerald from $76.00 to $113.00. They now have an “overweight” rating on the stock.
• 1/15/2025 – PTC Therapeutics had its price target lowered by analysts at Cantor Fitzgerald from $80.00 to $76.00. They now have an “overweight” rating on the stock.

PTC Therapeutics Stock Performance

Shares of NASDAQ:PTCT traded down $0.39 during midday trading on Thursday, reaching $50.05. The company’s stock had a trading volume of 137,467 shares, compared to its average volume of 683,587. PTC Therapeutics, Inc. has a fifty-two week low of $24.00 and a fifty-two week high of $54.16. The firm has a market capitalization of $3.86 billion, a price-to-earnings ratio of -8.43 and a beta of 0.62. The firm has a 50 day moving average price of $46.52 and a two-hundred day moving average price of $41.29.

Insiders Place Their Bets

In other news, EVP Lee Scott Golden sold 810 shares of the company’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $45.34, for a total value of $36,725.40. Following the completion of the transaction, the executive vice president now directly owns 79,849 shares of the company’s stock, valued at $3,620,353.66. This represents a 1.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Mark Elliott Boulding sold 85,600 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $52.26, for a total value of $4,473,456.00. Following the completion of the transaction, the vice president now owns 92,389 shares in the company, valued at approximately $4,828,249.14. The trade was a 48.09 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 211,737 shares of company stock valued at $10,920,687. Corporate insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On PTC Therapeutics

Institutional investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. increased its holdings in shares of PTC Therapeutics by 7.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 706,730 shares of the biopharmaceutical company’s stock worth $26,220,000 after purchasing an additional 47,902 shares during the period. Two Sigma Advisers LP increased its stake in PTC Therapeutics by 10.3% in the third quarter. Two Sigma Advisers LP now owns 429,842 shares of the biopharmaceutical company’s stock valued at $15,947,000 after acquiring an additional 40,300 shares during the last quarter. Intech Investment Management LLC bought a new position in PTC Therapeutics in the third quarter valued at $698,000. Quest Partners LLC increased its stake in PTC Therapeutics by 433.9% in the third quarter. Quest Partners LLC now owns 22,359 shares of the biopharmaceutical company’s stock valued at $830,000 after acquiring an additional 18,171 shares during the last quarter. Finally, State Street Corp grew its stake in shares of PTC Therapeutics by 5.4% during the third quarter. State Street Corp now owns 2,899,040 shares of the biopharmaceutical company’s stock valued at $107,554,000 after buying an additional 149,700 shares during the last quarter.

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.